Prevalence, classifications and factors associated with sexual dysfunction among adult cancer patients on chemotherapy at the Uganda Cancer Institute, Mbarara.
Humans
Male
Female
Middle Aged
Uganda
/ epidemiology
Neoplasms
/ drug therapy
Cross-Sectional Studies
Prevalence
Sexual Dysfunction, Physiological
/ chemically induced
Adult
Risk Factors
Antineoplastic Agents
/ adverse effects
Aged
Surveys and Questionnaires
Sexual Dysfunctions, Psychological
/ epidemiology
Anorgasmia
Anthracyclines
Chemotherapy
Dyspareunia
Erectile dysfunction
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
30 Sep 2024
30 Sep 2024
Historique:
received:
29
04
2024
accepted:
24
09
2024
medline:
1
10
2024
pubmed:
1
10
2024
entrez:
30
9
2024
Statut:
epublish
Résumé
Sexual dysfunction is a social challenge that devastates many people, including cancer patients. However, among the numerous reported side effects of chemotherapy sexual dysfunction is the least studied and reported. The chemotherapeutics used among cancer patients are potential risk factors for the development of sexual dysfunction, and such an understanding of these risk factors can lead to numerous interventions to bypass their effects on sexual activity. The goal of this study was to determine the prevalence, classification and factors associated with sexual dysfunction among cancer patients receiving chemotherapy. A cross-sectional study was conducted among 214 cancer patients at the Mbarara Regional Referral Hospital in southwestern Uganda for a period of 3 months from August to October 2023. A systematic sampling technique was employed in the study; a questionnaire was used to collect patient data. The standardized female sexual function index and international index of erectile function tools were used to classify types of sexual dysfunctions among women and men, respectively. Sexual dysfunction-associated factors were analyzed by logistic regression using Stata version 17. A total of 127 males and 87 females with a median age of 50 years were enrolled. Overall (42.1%) of the patients, (54.3%) males and (24.1%) females experienced sexual dysfunction. (33.9%) of male reported overall sexual dissatisfaction, while among female (18.4%) patients reported decreased sexual desire. while others reported reduced arousal and vaginal pain. Multivariate logistic regression revealed the following independent risk factors for sexual dysfunctions: male sex (AOR 3.99, 95% CI 1.93-8.25; p value = 0.001), gastrointestinal cancer (AOR 3.46, 95% CI 1.34-8.93; p value = 0.010) and anthracyclines use (AOR 4.26, 95% CI 1.02, 17.76; p value = 0.047). Our findings suggest that there is a high prevalence of sexual dysfunction among cancer patients at the Mbarara Regional Referral Hospital. In male patients, overall sexual dissatisfaction is the most prevalent, while decreased sexual desire is prevalent in females. Routine screening of sexual functions should be encouraged for all patients receiving chemotherapies. Males patients, those diagnosed with gastrointestinal cancers and those receiving regimens containing anthracyclines should be more closely monitored for sexual dysfunction.
Sections du résumé
BACKGROUND
BACKGROUND
Sexual dysfunction is a social challenge that devastates many people, including cancer patients. However, among the numerous reported side effects of chemotherapy sexual dysfunction is the least studied and reported. The chemotherapeutics used among cancer patients are potential risk factors for the development of sexual dysfunction, and such an understanding of these risk factors can lead to numerous interventions to bypass their effects on sexual activity.
OBJECTIVE
OBJECTIVE
The goal of this study was to determine the prevalence, classification and factors associated with sexual dysfunction among cancer patients receiving chemotherapy.
METHODS
METHODS
A cross-sectional study was conducted among 214 cancer patients at the Mbarara Regional Referral Hospital in southwestern Uganda for a period of 3 months from August to October 2023. A systematic sampling technique was employed in the study; a questionnaire was used to collect patient data. The standardized female sexual function index and international index of erectile function tools were used to classify types of sexual dysfunctions among women and men, respectively. Sexual dysfunction-associated factors were analyzed by logistic regression using Stata version 17.
RESULTS
RESULTS
A total of 127 males and 87 females with a median age of 50 years were enrolled. Overall (42.1%) of the patients, (54.3%) males and (24.1%) females experienced sexual dysfunction. (33.9%) of male reported overall sexual dissatisfaction, while among female (18.4%) patients reported decreased sexual desire. while others reported reduced arousal and vaginal pain. Multivariate logistic regression revealed the following independent risk factors for sexual dysfunctions: male sex (AOR 3.99, 95% CI 1.93-8.25; p value = 0.001), gastrointestinal cancer (AOR 3.46, 95% CI 1.34-8.93; p value = 0.010) and anthracyclines use (AOR 4.26, 95% CI 1.02, 17.76; p value = 0.047).
CONCLUSIONS
CONCLUSIONS
Our findings suggest that there is a high prevalence of sexual dysfunction among cancer patients at the Mbarara Regional Referral Hospital. In male patients, overall sexual dissatisfaction is the most prevalent, while decreased sexual desire is prevalent in females. Routine screening of sexual functions should be encouraged for all patients receiving chemotherapies. Males patients, those diagnosed with gastrointestinal cancers and those receiving regimens containing anthracyclines should be more closely monitored for sexual dysfunction.
Identifiants
pubmed: 39350106
doi: 10.1186/s12885-024-12987-z
pii: 10.1186/s12885-024-12987-z
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1209Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
doi: 10.3322/caac.21660
pubmed: 33538338
https://gco.iarc.who.int/media/globocan/factsheets/populations/800-uganda-fact-sheet.pdf
Maiorino et al. 2022 [Internet]. [Cited 2023 Mar 29]. https://link.springer.com/article/10.1007/s40618-018-0872-6
Agboola SO, Ju W, Elfiky A, Kvedar JC, Jethwani K. The Effect of Technology-based interventions on Pain, Depression, and quality of life in patients with Cancer: a systematic review of Randomized controlled trials. J Med Internet Res. 2015;17(3):e4009.
doi: 10.2196/jmir.4009
Chen CH, Lin YC, Chiu LH, Chu YH, Ruan FF, Liu WM et al. Female sexual dysfunction: Definition, classification, and debates. Taiwanese Journal of Obstetrics and Gynecology [Internet]. 2013 Mar 1 [cited 2022 Oct 3]; 52(1):3–7. https://www.sciencedirect.com/science/article/pii/S102845591300003X
Cakar B, Karaca B, Uslu R. Sexual dysfunction in cancer patients: a review.: 6.
Heyne S, Esser P, Geue K, Friedrich M, Mehnert-Theuerkauf A. Frequency of sexual problems and related psychosocial characteristics in cancer patients—findings from an epidemiological multicenter study in Germany. Front Psychol [Internet]. 2021 Jul 22 [cited 2022 Oct 3]; 12:679870. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339199/
Akkuzu G, Ayhan A. Sexual functions of Turkish women with gynecologic cancer during the chemotherapy process. Asian Pac J Cancer Prev. 2013;14(6):3561–4.
doi: 10.7314/APJCP.2013.14.6.3561
pubmed: 23886145
Odigie VI, Tanaka R, Yusufu LMD, Gomna A, Odigie EC, Dawotola DA et al. Psychosocial effects of mastectomy on married African women in Northwestern Nigeria. Psycho-Oncology [Internet]. 2010 [cited 2022 Oct 9]; 19(8):893–7. https://onlinelibrary.wiley.com/doi/abs/ https://doi.org/10.1002/pon.1675
Obora M, Onsongo L, Ogutu JO. Determinants of sexual function among survivors of gynaecological cancers in a tertiary hospital: a cross-sectional study [Internet]. 2022 [cited 2022 Nov 9]. http://ecancer.org/en/journal/article/1384-determinants-of-sexual-function-among-survivors-of-gynaecological-cancers-in-a-tertiary-hospital-a-cross-sectional-study
Baumgart j nilson k. Medline
Almont T, Bouhnik AD, Ben Charif A, Bendiane MK, Couteau C, Manceau C, et al. Sexual health problems and discussion in Colorectal Cancer patients two years after diagnosis: a National Cross-sectional Study. J Sex Med. 2019;16(1):96–110.
doi: 10.1016/j.jsxm.2018.11.008
pubmed: 30621928
Allameh F, Azghandi S, Karkan MF. Is chemotherapy related with erectile dysfunction in non-urologic cancer patients? Int J Cancer Manag [Internet]. 2018 [cited 2022 Oct 14]; 11(9). https://brieflands.com/articles/ijcm-82529.html#abstract
Pizzol D, Xiao T, Smith L, Sánchez GFL, Garolla A, Parris C, et al. Prevalence of erectile dysfunction in male survivors of cancer: a systematic review and meta-analysis of cross-sectional studies. Br J Gen Pract. 2021;71(706):e372–80.
doi: 10.3399/bjgp20X714197
pubmed: 33926885
pmcid: 8087306
Eeltink CM, Incrocci L, Witte BI, Meurs S, Visser O, Huijgens P, et al. Fertility and sexual function in female Hodgkin lymphoma survivors of reproductive age. J Clin Nurs. 2013;22(23–24):3513–21.
doi: 10.1111/jocn.12354
pubmed: 23808758
Rizzuto I, Oehler MK, Lalondrelle S. Sexual and psychosexual consequences of treatment for gynaecological cancers. Clinical Oncology [Internet]. 2021 Sep 1 [cited 2022 Aug 7]; 33(9):602–7. https://www.clinicaloncologyonline.net/article/S0936-6555(21)00262-4/fulltext
Jung SH. Stratified Fisher’s exact test and its sample size calculation. Biometrical J Biometrische Z. 2014;56:129–40.
doi: 10.1002/bimj.201300048
Rosen C, Brown J, Heiman S, Leib R. The female sexual function index (FSFI): a multidimensional self-report instrument for the Assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191–208.
doi: 10.1080/009262300278597
pubmed: 10782451
Obora M, Onsongo L, Ogutu JO. Determinants of sexual function among survivors of gynaecological cancers in a tertiary hospital: a cross-sectional study [Internet]. 2022 [cited 2023 Sep 11]. http://ecancer.org/en/journal/article/1384-determinants-of-sexual-function-among-survivors-of-gynaecological-cancers-in-a-tertiary-hospital-a-cross-sectional-study
Mohamad Muhit AM, Sy-Cherng Woon L, Nik Mhd Nor NS, Sidi H, Mohd Kalok AH, Kampan N@ C, et al. Sexual dysfunction among Gynaecological Cancer survivors: a descriptive cross-sectional study in Malaysia. Int J Environ Res Public Health. 2022;19(23):15545.
doi: 10.3390/ijerph192315545
pubmed: 36497627
pmcid: 9737182
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(6):822–30.
doi: 10.1016/S0090-4295(97)00238-0
pubmed: 9187685
Vomvas D, Iconomou G, Soubasi E, Leotsinidis M, Kalofonos HP, Beratis S, et al. Assessment of sexual function in patients with cancer undergoing radiotherapy–a single centre prospective study. Anticancer Res. 2012;32(2):657–64.
pubmed: 22287759
Stal J, Yi SY, Cohen-Cutler S, Gallagher P, Barzi A, Freyer DR, et al. Sexual dysfunction among early-onset colorectal cancer survivors: sex-specific correlates of sexual health discussions between patients and providers. Cancer Causes Control. 2024;35(1):111–20.
doi: 10.1007/s10552-023-01772-1
pubmed: 37597065
Greenberg DR, Khandwala YS, Bhambhvani HP, Simon PJ, Eisenberg ML. Male and female sexual dysfunction in Pediatric Cancer survivors. J Sex Med. 2020;17(9):1715–22.
doi: 10.1016/j.jsxm.2020.05.014
pubmed: 32622765
Heyne S, Esser P, Geue K, Friedrich M, Mehnert-Theuerkauf A. Frequency of sexual problems and related psychosocial characteristics in Cancer patients-findings from an epidemiological Multicenter Study in Germany. Front Psychol. 2021;12:679870.
doi: 10.3389/fpsyg.2021.679870
pubmed: 34367002
pmcid: 8339199
Bond CB, Jensen PT, Groenvold M, Johnsen AT. Prevalence and possible predictors of sexual dysfunction and self-reported needs related to the sexual life of advanced cancer patients. Acta Oncol. 2019;58(5):769–75.
doi: 10.1080/0284186X.2019.1566774
pubmed: 30724646
Hovén E, Fagerkvist K, Jahnukainen K, Ljungman L, Lähteenmäki PM, Axelsson O, et al. Sexual dysfunction in young adult survivors of childhood cancer – A population-based study. Eur J Cancer. 2021;154:147–56.
doi: 10.1016/j.ejca.2021.06.014
pubmed: 34273812
Hendren SK, O’Connor BI, Liu M, Asano T, Cohen Z, Swallow CJ, et al. Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer. Ann Surg. 2005;242(2):212–23.
doi: 10.1097/01.sla.0000171299.43954.ce
pubmed: 16041212
pmcid: 1357727
Camara A, Tounkara TM, Delamou A, Baldé R, Leno NN, Kuotu GC et al. Prevalence and risk factors of female sexual dysfunction among women infected with HIV in conakry. Clinical Epidemiology and Global Health [Internet]. 2021 Oct 1 [cited 2023 Sep 11]; 12. https://cegh.net/article/S2213-3984(21)00136-6/fulltext
Alananzeh I, Green H, Meedya S, Chan A, Chang HC (Rita), Yan Z Sexual activity and cancer, et al. editors. A systematic review of prevalence, predictors and information needs among female Arab cancer survivors. European Journal of Cancer Care. 2022; 31(6):e13644.
Gabrielson AT, Sartor RA, Hellstrom WJG. The impact of thyroid disease on sexual dysfunction in men and women. Sex Med Reviews. 2019;7(1):57–70.
doi: 10.1016/j.sxmr.2018.05.002
Mazzola CR, Mulhall JP. Impact of androgen deprivation therapy on sexual function. Asian J Androl. 2012;14(2):198–203.
doi: 10.1038/aja.2011.106
pubmed: 22231298
pmcid: 3735098
Wilson SJ, Gelovani D, Von A, Kaatz S, Grant PJ. Medical clinics of North America—periprocedural antithrombotics: prophylaxis and interruption. Medical Clinics [Internet]. 2024 Jul 31 [cited 2024 Sep 19]; 0(0). https://www.medical.theclinics.com/article/S0025-7125(24)00052-X/abstract
Traish AM, Guay AT. Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. J Sex Med. 2006;3(3):382–404. discussion 404–407.
doi: 10.1111/j.1743-6109.2006.00245.x
pubmed: 16681465
Kim NK, Aahn TW, Park JK, Lee KY, Lee WH, Sohn SK, et al. Assessment of sexual and voiding function after total Mesorectal Excision with Pelvic autonomic nerve preservation in males with rectal Cancer. Dis Colon Rectum. 2002;45(9):1178.
doi: 10.1007/s10350-004-6388-5
pubmed: 12352233
Traa MJ, Vries JD, Roukema JA, Oudsten BLD. Sexual (dys)function and the quality of sexual life in patients with colorectal cancer: a systematic review. Ann Oncol. 2012;23(1):19–27.
doi: 10.1093/annonc/mdr133
pubmed: 21508174
Sörensson M, Asplund D, Matthiessen P, Rosenberg J, Hallgren T, Rosander C, et al. Self-reported sexual dysfunction in patients with rectal cancer. Colorectal Dis. 2020;22(5):500–12.
doi: 10.1111/codi.14907
pubmed: 31713295
Krouwel EM, Kramer Z, Gordijn R, Nicolai MPJ, Osanto S, Putter H, et al. Sexual and fertility-related adverse effects of medicinal treatment for cancer; a national evaluation among medical oncologists. Support Care Cancer. 2022;30(5):4035–47.
doi: 10.1007/s00520-021-06721-9
pubmed: 35064326
Krychman ML, Carter J, Aghajanian CA, Dizon DS, Castiel M. Chemotherapy-induced dyspareunia: a case study of vaginal mucositis and pegylated liposomal doxorubicin injection in advanced stage ovarian carcinoma. Gynecol Oncol. 2004;93(2):561–3.
doi: 10.1016/j.ygyno.2004.02.001
pubmed: 15099982